Distinguishing aggressive prostate cancer from indolent disease represents an important
clinical challenge, because current therapy may lead to overtreatment of men with limited
disease. The prostate-specific membrane antigen (PSMA) is a membrane-bound
glycoprotein that is highly restricted to the prostate. Previously, studies analyzing the
expression of PSMA have found an up-regulation in correlation with prostate cancer,
particularly in advanced cancer. This association is ideal for an application as a prognostic …